Prostacyclin's Effect on Platelet Responsiveness

Catholic University of the Sacred Heart

Status and phase

Completed

Phase 4

Conditions

Acute Kidney Failure

Treatments

Drug: prostacyclin

Drug: heparin

Study type

Interventional

Funder types

Other

Identifiers

NCT00890214

AABR-0609

Details and patient eligibility

About

The researchers investigated the influence of a prostacyclin analogue (PGIA) versus unfractionated heparin (UFH) on ex vivo platelet function, during continuous venovenous hemodiafiltration.

Full description

Context and purpose of the study: Prospective, randomized comparison of a PGIA versus UFH as circuit anticoagulant. Platelet responsiveness was assessed from peripheral blood by light-transmittance aggregometry (LTA) induced by collagen and ADP, at baseline, 4 and 24 hrs after treatment onset. Platelet function was also assessed in blood samples collected in the circuit before and after the filter. The Setting was a University Hospital Intensive Care Unit. 23 ICU patients with Acute Renal Failure needing CVVHDF were studied during standard CVVHDF therapy, at random infusion in the extracorporeal circuit of PGIA or UFH.

Enrollment

23 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

critically patients ill patients with acute kidney failure (AKI) needing renal replacement therapy

Exclusion criteria

therapy with aspirin or other non-steroidal anti-inflammatory drugs in the previous 7 days
concomitant treatment with other extracorporeal organ-assist devices any other drug affecting coagulation or platelets